In the last trading session, the stock price of Kadmon Holdings Inc (NYSE:KDMN) gained 0.20% to close the day at $4.96. The gains came at a share volume of 737,647 compared to average share volume of 631,757.
The buzz
Last month, Kadmon Holdings posted additional positive data from an underway Phase II clinical study demonstrating that KD025 was well tolerated and led in clinically notable responses in people with chronic graft-versus-host disease. New report from Cohort 2 of the study demonstrated an Overall Response Rate of 63% (Data cutoff date – November 20, 2017). Updated report from Cohort 1 demonstrated an ORR of 65%.
While report from Cohort 2 sustains to mature, outcomes were durable in Cohort 1, prevailing five months or longer in as many as 70% of subjects. Responses were even fast: 71% of subjects across Cohorts 1 and 2 recorded responses by the first assessment after eight weeks of treatment. Responses were noted across all affected organs, counting Complete Responses in lower and upper gastrointestinal tract, skin, joints, mouth, eyes, liver and esophagus.
In addition, 64% of subjects from Cohorts 1 and 2 lowered steroid dose, and four subjects completely discontinued steroids. Eighty-three percent of patients lowered dose of tacrolimus, another immunosuppressive agent utilized to cure cGVHD. As pet the report, KD025 was well tolerated, and no drug-related SAEs were noted in either cohort.
cGVHD marks as a common and often fatal problem after hematopoietic stem cell transplantation, a process that is often used to cure patients with cancers like leukemia or myeloma. With cGVHD, graft attack the patient’s cells, leading to fibrosis and inflammation in several tissues, including mouth, skin, liver, lung, eye, joints, GI tract and esophagus.
Kadmon Holdings is a fully integrated biopharma firm advancing unique products for considerable unmet medical needs. They boast a product pipeline with a focus on fibrotic and autoimmune diseases.
